- Safety, Utility, and Outcomes of Procainamide Challenge for the Diagnosis and Exclusion of Brugada Syndrome
- Mitochondrial Genetics in Cardiovascular Health and Disease: A Scientific Statement From the American Heart Association
- Oxidized Phospholipids, Lipoprotein(a), and Cardiovascular Outcomes after Acute Coronary Syndrome
- Response by Abdel-Qadir et al to Letter Regarding Article, “Bleeding and New Malignancy Diagnoses After Anticoagulation for Atrial Fibrillation: A Population-Based Cohort Study”
- Transcatheter Aortic Valve Replacement With Local Anesthesia: When Less Is Less?
- Response by Patel and Giugliano to Letter Regarding Article, “Efficacy and Safety of Non–Vitamin K Antagonist Oral Anticoagulants Versus Warfarin Across the Spectrum of Body Mass Index and Body Weight: An Individual Patient Data Meta-Analysis of 4 Randomized Clinical Trials of Patients With Atrial Fibrillation”
- Chordin-Like 1 mRNA Therapy for Acute Myocardial Infarction
- Letter by Hu et al Regarding Article, “Efficacy and Safety of Non–Vitamin-K Antagonist Oral Anticoagulants Versus Warfarin Across the Spectrum of Body Mass Index and Body Weight: An Individual Patient Data Meta-Analysis of 4 Randomized Clinical Trials of Patients With Atrial Fibrillation”
- Letter by Wu et al Regarding Article, “Bleeding and New Malignancy Diagnoses After Anticoagulation for Atrial Fibrillation: A Population-Based Cohort Study”
- When Diagnostic Criteria Redefine Disease: Lessons From the Padua and European Task Force Criteria
- The Diagnostic Challenge of Irregular Tachycardia Accompanied by Alternating Bundle Branch Block
- Leveraging a Genetic Proxy to Investigate the Effects of Lifelong Cardiac Sodium Channel Blockade
- Time for Precision Medicine in Atrial Fibrillation Management? Not So Fast.
- Proteomic Signatures Involved in Cardiac Recovery After Mechanical Unloading
- Letter by Chen Regarding Article, “Dose Response of Incidental Physical Activity Against Cardiovascular Events and Mortality”
